Q&A: Sundia Meditech

Yu Jihui, CFO of Sundia Meditech Company, a Chinese subcontractor performing R&D outsourced by big pharma and biotech companies, tells CT how it limits its euro exposure, the benefits of banking with China’s non-state-owned lenders and why it’s delaying its IPO.
Q&A: Sundia Meditech
By I-Ching Ng
Jun 11, 2012
linkedinfacebooktwitter

Q: How’s your company’s treasury function defined?

Sign in to read on!


Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to CorporateTreasurer.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.
If you are a treasurer, CFO or senior financial professional at a corporate or SME, please register for free VIP access here.

Questions?

See here for more information on licences and prices, or contact [email protected].
© Haymarket Media Limited. All rights reserved.
MovesInterviews
biotechcfoeurohedgingipopharmaq&arenminbirmbsundia meditechyu jihui
Sign up for CorporateTreasurer’s Newsletter
Top news, insights and analysis every Tuesday & Thursday
Free registration gives you access to our email newsletters
Become a CorporateTreasurer Subscriber
for unlimited access to all articles, newsletters

Related Articles